It is well known that about 1% of the population in western countries suffers from congestive heart failure (CHF). Its annual incidence in the adult population of the Framingham study in the late 1960s was 0.23% in men and 0.14% in women, the main cause being hypertension. Since that time, the control of hypertension has much improved, bUI the simultaneously reduced mortality from acute coronary heart disease has resulted in an increasing incidence of chronic CHF. In the same famous study, the mortality from CHF was also established as being extremely high, and CHF usually killed victims faster than most malignant neoplasms. The mortality figures, which are not much influenced by the causes of CHF, range from 30% within 3 years of diagnosis to 70% at I year. About half of the victims die from progressive pump failure, the other half being sudden deaths related to arrhythmias.
Consequently, it is estimated that in Finland there are at least 50,000 patients suffering from progressive CHF. However, the number of patients receiving digoxin therapy in this country is about 300,000, which clearly reveals the problems in defining and diagnosing CHF. The present division of the old unitary concept ofCHF into systolic and diastolic ventricular dysfunction undoubtedly facilitates the therapeutic decision making. However, new questions have arisen with the numerous new alternatives in drug therapy.
The fundamental symptoms of CHF are dyspnoea and fatigue. Dyspnoea is due to elevated left ventricular (LV) filling pressure, resulting from LV diastolic dysfunction; fatigue is due to systolic LV dysfunction, resulting in low cardiac output relative to body requirements. About 60% of patients with symptomatic heart failure suffer from systolic and diastolic LV dysfunction; the majority of the remainder having diastolic LV dysfunction only. We know now that these basic abnormalities further activate 2 important neuroendocrine systems, the sympathoadrenal system and the reninangiotensin system. These advance the clinical picture from a rather nonspecific one towards that of overt CHF, consisting of fluid retention, sinus tachycardia, arrhythmias, cardiomegaly and peripheral vasoconstriction. The complexity of the disturbances contributing to the clinical syndrome of CHF means that a more or less different pharmacological approach is required for each one of the above abnormalities.
For the basic disturbance, an inotropic agent would be needed to improve myocardial contractility. In spite of the vast clinical progress in the treatment of the secondary pathophysiological mechanisms of CHF, progress in the treatment of the failing myocardium has been rather modest. The old-fashioned, and in recent years more or less disfavoured, digoxin has lately been rehabilitated and shown to possess a weak but definite positive inotropic effect on the heart, even during sinus rhythm. Thus, it has regained its place as the only agent licensed for monotherapy, despite the drawbacks of its toxicity and narrow therapeutic range. It is effective only in well-established CHF, since in mild CHF it may be detrimental because of its enhancing effect on peripheral resistance. New oral inotropic agen~s such as full adrenergic agonists, phosphodiesterase innibitors and other agents with unclear mechanisms of action, have exhibited varying toxicities in long term use. Xamoterol, a partial ~t-agonist, was recently compared with digoxin in a large European multicentre study (German and Austrian Xamoterol Study Group 1988) . It was found to moderately enhance the contractility of the failing myocardium and to be suitable for long term use, because of a low incidence of side effects and tachyphylaxis. Its inotropic activity was reported to exceed that of digoxin in mild and moderate CHF, but probably not in severe CHF. In addition to maintaining cardiac contractility, it protects the failing heart against adrenergic overstimulation by occupying myocardial f3t-adrenoceptors. A special feature of this agent seems to be its property of improving myocardial diastolic relaxation.
Diuretics relieve the symptoms caused by fluid retention and are currently considered the first drugs for use in CHF. However, they do not improve contractility, readily produce potassium, sodium and magnesium depletion, and when used incautiously, may easily lead to a reduction in ejection fraction. A further drawback is their activation of the renin-angiotensin system.
Vasodilators have lately been accepted as an important part of the drug therapy of CHF. However, tachyphylaxis limits the long term use of some effective vasodilators, such as hydralazine, prazosin and related substances, and most vasodilators stimulate the sympathoadrenal and reninangiotensin systems. However, nitrates and particularly ACE inhibitors have proven effective even in long term treatment. These agents ameliorate the symptoms, improve the exercise capacity and alter the prognosis of patients with CHF.
There are 2 prospective randomised double-
blind studies on the effect of vasodilators on the outlook for patients with CHF. In the Veterans Administration Cooperative Study of Survival in Heart Failure (Cohn et al. 1986 ), a combination of hydralazine and isosorbide dinitrate was added to the existing digitalis and diuretic therapy in male patients with mild or moderate CHF. This treatment resulted in a small but significant reduction in cumulative mortality during 42 months of follow-up, compared with the placebo group. In the Scandinavian CONSENSUS study (CONSENSUS Study Group 1987) , enalapril was added to the existing therapy in male and female patients with severe CHF mainly due to ischaemic heart disease. In this study an even greater mortality reduction was achieved during 1 year offollow-up. Mortality was reduced by 40% at the end of 6 months and 31 % at the end of the first year, compared with the placebo group. A comparable functional improvement was also found in a double-blind study comparing the effect of digoxin and captopril in mild or moderate CHF. Consequently, ACE inhibitors seem to be superior to the other vasodilators in the treatment of CHF, presumably because they block the renin-angiotensin system and suppress the sympathoadrenal influences on the heart. There is a growing interest in introducing ACEinhibitor therapy earlier in CHF, perhaps even instead of diuretics. Two independent studies were recently reported, in which the effect of captopril on postinfarction ventricular dysfunction with low ejection fraction was investigated (Pfeffer et al. 1988; Sharpe et al. 1988) . These preliminary trials indicated that marked ventricular enlargement after myocardial infarction is progressive and associated with deteriorating systolic function and that captopril attenuates this post-infarction ventricular remodelling process, whereas diuretics or placebo do not. Two large multicentre studies are currently being carried out to evaluate in large-scale clinical settings the importance of early intervention with ACE inhibitors after acute myocardial infarction.
ACE inhibitors may represent the most important advance in the treatment of CHF since the introduction of the oral diuretics. There are several issues regarding the use of these important drugs in LV dysfunction and CHF syndrome which could be discussed. The following are the most important of these:
• Should ACE inhibitors be introduced to all patients with CHF, if no contraindications exist, or should they be reserved for use in severe CHF?
• Should ACE inhibitors be the initial drug treatment in CHF?
• Is it necessary to add an inotropic agent such as digitalis to the treatment of moderate to severe CHF with ACE inhibitors and diuretics?
• Should ACE-inhibitor therapy be routinely started in cases of marked postinfarction LV dysfunction?
• In mild to moderate CHF would it be rational to use an additive drug regimen combining diuretics, ACE inhibitors and xamoterol? Dr Jay Cohn recently proposed the following regimen (J. Cohn, personal communication): diuretics to prevent fluid retention, ACE inhibit{)fs for vasodilatation and suppression of the renin-angiotensin system, and xamoterol to protect the myocardium against excessive sympathetic stimulation, maintain contractility and improve diastolic function.
The present era brings new approaches in the treatment of CHF. The potential of ACE inhibitors
